当前位置:首页 > 报告详情

传奇 2025 Legend Corporate Presentation 1.14.25.pdf

上传人: c** 编号:604024 2025-02-03 29页 2.59MB

1、1Legend BiotechCORPORATE PRESENTATIONJANUARY 14,20252DisclaimerThis presentation has been prepared by Legend Biotech Corporation(“Legend Biotech”or the“Company”)solely for information purpose and does not contain all relevant information relating to the Company.The safety and efficacy of the agents

2、and/or uses under investigation discussed in this presentation have not been established,except to the extent specifically provided by marketing authorizations previously received from relevant health authorities.Further,for investigational agents and/or uses,the Company cannot guarantee health auth

3、ority approval or that such agents and/or uses will become commercially available in any country.Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies,publications,surveys and other data obtained from third-party sour

4、ces and Legend Biotechs own internal estimates and research.While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation,it has not independently verified,and makes no representation as to the adequacy,fairness,accuracy or completeness of,any information

5、 obtained from third-party sources.While Legend Biotech believes its internal research is reliable,such research has not been verified by any independent source.Statements in this presentation about future expectations,plans and prospects,as well as any other statements regarding matters that are no

6、t historical facts,constitute“forward-looking statements”within the meaning of The Private Securities Litigation Reform Act of 1995.These statements include,but are not limited to,statements relating to Legend Biotechs strategies and objectives;statements relating to CARVYKTI(ciltacabtagene autoleuc

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据报告的内容,本文主要介绍了Legend Biotech Corporation(Legend Biotech)的企业概况、产品管线、市场表现和未来规划。 1. Legend Biotech是一家专注于细胞治疗药物研发和生产的生物制药公司,拥有超过2500名员工,其中450多名专注于研发。 2. Legend Biotech的主要产品是CAR-T细胞疗法CARVYKTI®(ciltacabtagene autoleucel;cilta-cel),用于治疗多发性骨髓瘤。CARVYKTI®是全球首款也是唯一一款在多发性骨髓瘤治疗中显示出优于标准治疗方案的CAR-T细胞疗法。 3. CARVYKTI®自上市以来,销售业绩持续增长,2024年第三季度净贸易销售额达到2.86亿美元。Legend Biotech计划通过扩大社区渗透率、更新整体生存期标签和增加门诊程序等方式,进一步扩大CARVYKTI®的市场领导地位。 4. Legend Biotech正在开发下一代CAR-T产品,包括针对实体瘤的多种装甲CAR-T策略,以及针对自身免疫疾病的治疗方案。其中,LB2102是一种针对小细胞肺癌的DLL3靶向CAR-T疗法,已获得美国FDA的孤儿药资格。 5. Legend Biotech计划在未来几年内,通过扩大生产能力、推进临床研究和加强市场渗透,进一步提升其在细胞治疗领域的领导地位。
传奇生物如何利用CARVYKTI®在多发性骨髓瘤治疗领域保持领先地位? 传奇生物的CAR-T管线中,哪些新药有望成为下一个CARVYKTI®? 传奇生物如何通过全球制造网络扩大CARVYKTI®的供应,以满足不断增长的市场需求?
客服
商务合作
小程序
服务号
折叠